CorrespondenceIncreased use of healthcare resources during the preclinical period of inflammatory bowel disease
Section snippets
Author contributions
IR-L and MB-A: conceived the study and its design, analyzed and interpreted the data and drafted the manuscript.
UA: performed the statistical analysis.
NI and DC: provided the data.
JLC and MB-A: revised the manuscript for important intellectual content.
All authors have significantly contributed and accepted the final version of the manuscript.
Funding
IRL-L is supported by a research grant from Biocruces Bizkaia Health Research Institute [Grant No INT-BC-2018-007] and Gobierno Vasco-Eusko Jaurlaritza [Grant No 2020222004].
Declaration of Competing Interest
IR-L has received financial support for travelling and educational activities from or has served as an advisory board member for MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Shire Pharmaceuticals, Roche, Celltrion, Faes Farma, Ferring, Dr. Falk Pharma, Otsuka Pharmaceutical and Adacyte. Financial support for research from Tillotts Pharma.
MB-A has received financial support for travelling and educational activities from or has served as an advisory board member for Pfizer, MSD, Takeda,
References (9)
- et al.
Serum Biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis
Gastroenterology
(2020) - et al.
Characteristics and progression of preclinical inflammatory bowel disease
Clin Gastroenterol Hepatol
(2018) - et al.
Early microscopic findings in preclinical inflammatory bowel disease
Dig Liver Dis
(2020) - et al.
Understanding and preventing the global increase of inflammatory Bowel disease
Gastroenterology
(2017)
Cited by (3)
Recent Advances and Potential Multi-Omics Approaches in the Early Phases of Inflammatory Bowel Disease
2023, Journal of Clinical MedicineSubclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
2023, United European Gastroenterology JournalEarly Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
2022, Inflammatory Bowel Diseases
- 1
Both authors share co-senior authorship.